---
figid: PMC4367559__tlcr-01-03-179-f1
figtitle: MET/HGF signaling and functional cross-talk with other pathways
organisms:
- NA
pmcid: PMC4367559
filename: tlcr-01-03-179-f1.jpg
figlink: /pmc/articles/PMC4367559/figure/f1/
number: F1
caption: Schematic representation of MET/HGF signaling and functional cross-talk with
  other pathways. Hepatocyte growth factor (HGF) binds to MET receptor and activates
  kinase activity which then phosphorylates the docking site and recruits effector
  molecules [Growth factor receptor-bound protein 2 (GRB2), GRB2-associated-binding
  protein 1 (GAB1), SRC homology 2 domain-containing phosphatase 2 (SHP2), Son of
  sevenless-1 (SOS-1) and Sarcoma non-receptor tyrosine kinase (SRC)]. Downstream
  signaling pathways such as the Mitogen-activated protein kinase (ERK/MAPK) pathway,
  the Phosphatidylinositol 3 kinase (PI3K-AKT) pathway and the Phospholipase-Cγ (PLC-γ)
  pathway are activated. These effector pathways are shared by the epidermal growth
  factor receptor (EGFR/EGF) pathway, the vascular epidermal growth factor (VEGFR-2/VEGF-A)
  pathway, the HER2 pathway and the EML4-ALK pathway. The signals affect gene expression
  and promote cell proliferation and survival, angiogenesis and cytoskeletal alterations
  resulting in cancer growth and progression. EGFR and HER2 can Trans-phosphorylate
  and activate MET. MET activation increases transcriptional expression of VEGF-A
  and WNT ligand and activates VEGF pathway and WNT-β-catenin pathway, respectively.
  β-catenin increases MET expression.
papertitle: Role of HGF/MET axis in resistance of lung cancer to contemporary management.
reftext: Kanwal Pratap Singh Raghav, et al. Transl Lung Cancer Res. 2012 Sep;1(3):179-193.
year: '2012'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9306245
figid_alias: PMC4367559__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC4367559__F1
ndex: db6ea622-df0a-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4367559__tlcr-01-03-179-f1.html
  '@type': Dataset
  description: Schematic representation of MET/HGF signaling and functional cross-talk
    with other pathways. Hepatocyte growth factor (HGF) binds to MET receptor and
    activates kinase activity which then phosphorylates the docking site and recruits
    effector molecules [Growth factor receptor-bound protein 2 (GRB2), GRB2-associated-binding
    protein 1 (GAB1), SRC homology 2 domain-containing phosphatase 2 (SHP2), Son of
    sevenless-1 (SOS-1) and Sarcoma non-receptor tyrosine kinase (SRC)]. Downstream
    signaling pathways such as the Mitogen-activated protein kinase (ERK/MAPK) pathway,
    the Phosphatidylinositol 3 kinase (PI3K-AKT) pathway and the Phospholipase-Cγ
    (PLC-γ) pathway are activated. These effector pathways are shared by the epidermal
    growth factor receptor (EGFR/EGF) pathway, the vascular epidermal growth factor
    (VEGFR-2/VEGF-A) pathway, the HER2 pathway and the EML4-ALK pathway. The signals
    affect gene expression and promote cell proliferation and survival, angiogenesis
    and cytoskeletal alterations resulting in cancer growth and progression. EGFR
    and HER2 can Trans-phosphorylate and activate MET. MET activation increases transcriptional
    expression of VEGF-A and WNT ligand and activates VEGF pathway and WNT-β-catenin
    pathway, respectively. β-catenin increases MET expression.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - HGF
  - IL6
  - SOS1
  - ERBB2
  - EGF
  - VEGFA
  - EGFR
  - KDR
  - GAB1
  - PIGU
  - THBS1
  - PLCG1
  - PLCG2
  - GRB2
  - NOS3
  - ENO4
  - PTPN11
  - SHE
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - SRC
  - FGR
  - FYN
  - YES1
  - PTK2
  - AKT1
  - AKT2
  - AKT3
  - ALK
  - SHC1
  - SHC2
  - SHC3
  - SHC4
  - CTNNB1
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - MTOR
  - BAD
  - EPHB2
  - MAPK1
  - MAPK3
  - KRAS
  - HRAS
  - NRAS
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
